Insider · CIK 0001869837
Asher Chanan-Khan
Files at CLRB (Cellectar Biosciences, Inc.). First filing -, latest -.
In brief
Asher Chanan-Khan files SEC Form 4 as director at CLRB (Cellectar Biosciences, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Asher Chanan-Khan has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 7, 2026 | CLRB Cellectar Biosciences, Inc. | AGrant or award Stock option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Jul 8, 2026 |
| Feb 14, 2025 | CLRB Cellectar Biosciences, Inc. | AGrant or award Stock option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Feb 18, 2025 |
Questions about Asher Chanan-Khan
Answered from the filings on this page, as of the latest one.
Is Asher Chanan-Khan buying or selling?
Asher Chanan-Khan has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Asher Chanan-Khan's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Asher Chanan-Khan has 0.
Where does Asher Chanan-Khan file Form 4?
Asher Chanan-Khan has filed Form 4 at CLRB (Cellectar Biosciences, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.